{"id":190,"date":"2023-02-15T15:18:52","date_gmt":"2023-02-15T15:18:52","guid":{"rendered":"http:\/\/192.168.10.30\/?page_id=190"},"modified":"2023-02-15T15:18:52","modified_gmt":"2023-02-15T15:18:52","slug":"paradigm","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=190","title":{"rendered":"Paradigm"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study<\/p>\n\n\n\n

Trial summary:<\/strong> A phase I dose escalation trial followed by a phase II randomised, double blind trial of radiotherapy plus placebo versus radiotherapy plus olaparib for newly diagnosed GBM patients in whose tumours the MGMT promoter region is unmethylated and who would not be eligible for treatment with standard radical radiotherapy with concomitant and adjuvant temozolomide. Phase I aims to establish the maximum tolerated dose of olaparib when given in combination with radiotherapy. Phase II aims to obtain evidence that adding olaparib to radiotherapy improves overall survival in patients. It has an embedded dose escalation substudy of olaparib and temozolomide plus radiotherapy to establish the maximum tolerated dose of olaparib when given in combination with radiotherapy and temozolomide in patients in whose tumours the MGMT promoter region is methylated.<\/p>\n\n\n\n

RT QA summary:<\/h2>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td><\/td><\/td>\n<\/tr>\n
Planning Benchmark Case<\/td><\/td><\/td>\n<\/tr>\n
Dummy Run<\/td><\/td>Outlining and planning<\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td><\/td><\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td>All patients<\/td>\n<\/tr>\n
Dosimetry <\/td><\/td>\"\"<\/td>Within last 5 years<\/td>\n<\/tr>\n
QA Streamlining<\/td><\/td>\"\"<\/td>ROAM, BRIOCHe<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA contact:<\/strong> paradigmqa.enh-tr@nhs.net <\/p>\n\n\n\n

Chief investigator:<\/strong> Prof Anthony Chalmers<\/p>\n\n\n\n

Sponsor: <\/strong>NHS Greater Glasgow & Clyde and University of Glasgow<\/p>\n\n\n\n

Funder: <\/strong>CRUK and Astra Zeneca<\/p>\n\n\n\n

CTU contact: <\/strong>Lorna.Sweeting@glasgow.ac.uk<\/p>\n","protected":false},"excerpt":{"rendered":"

OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-190","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=190"}],"version-history":[{"count":2,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/190\/revisions"}],"predecessor-version":[{"id":195,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/190\/revisions\/195"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}